Psychiatric & Behavioral Solutions LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$15,645	1
2023	Research	$26,761	3
2022	Research	$114,717	4
2021	Research	$221,827	3
2020	Research	$215,682	5
2019	Research	$198,933	15

Breakdown

Who paid Research payments · program years 2019–2024

Otsuka Pharmaceutical Development & Commercialization, Inc. $686,662 15 payments
Janssen Research & Development, LLC $106,904 16 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $428,611 5 payments
A Multicenter, Randomized, Flexible-Dose, Double Blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder $112,052 2 payments
A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation $63,398 10 payments
A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $46,514 2 payments
A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole $44,336 2 payments
A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $36,755 2 payments
A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment $32,423 1 payment
A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $15,645 1 payment
A Randomized, Multicenter, Crossover Study to Assess the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Subjects With Major Depressive Disorder $11,083 5 payments
A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Borderline Personality Disorder. $2,750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.